DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis ...

Credit: Insmed. Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1. Treatment with brensocatib 10mg and 25mg significantly reduced the annual rate of pulmonary exacerbations in ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Bronchiectasis is a long-term lung condition where the airways stay widened and inflamed. These airway changes make it harder to breathe and clear mucus. People with bronchiectasis live with a ...

Brinsupri (brensocatib) is a new oral medicine approved to treat a long-term lung disease known as non-cystic fibrosis bronchiectasis (NCFB) in adults and children ages 12 or older. It works by ...

CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...

How finally accepting her diagnosis and being proactive with her health helped one woman manage her lung condition.

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...